Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
51 hedge funds and large institutions have $64.8M invested in Mersana Therapeutics in 2025 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 3 increasing their positions, 24 reducing their positions, and 16 closing their positions.
162% more capital invested
Capital invested by funds: $24.7M → $64.8M (+$40.1M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
4% more funds holding
Funds holding: 49 → 51 (+2)
18.9% less ownership
Funds ownership: 63.81% → 44.91% (-19%)
88% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DMKJ
David M. Knott Jr
|
+$2.12M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$1.9M |
| 3 |
GLF
Groupe la Francaise
Paris,
France
|
+$1.17M |
| 4 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$1.08M |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
+$898K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AV
Alamea Verwaltungs
Edison,
New Jersey
|
-$7.71M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.12M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.75M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.04M |
| 5 |
6CM
683 Capital Management
New York
|
-$776K |
MRSN Hedge Fund Activity: Q4 2025 in Review
51 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q4 2025, worth a combined $64.8M — up 162% from $24.7M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new MRSN positions and 16 closed out — a net gain of 2 holders — while 3 added to existing stakes and 24 trimmed.
The largest buyer was David M. Knott Jr, opening a new position worth an estimated $2.12M. The largest seller was Alamea Verwaltungs, cutting an estimated $7.71M.
- 51 institutional investors held Mersana Therapeutics (MRSN) as of Q4 2025, up from 49 in Q3 2025.
- Funds reported $64.8M of Mersana Therapeutics stock for Q4 2025, up 162% quarter-over-quarter.
- 18 funds opened new Mersana Therapeutics positions in Q4 2025 and 16 closed out, a net change of +2 holders.
- The largest Mersana Therapeutics buyer in Q4 2025 was David M. Knott Jr, an estimated $2.12M added.
- The largest Mersana Therapeutics seller in Q4 2025 was Alamea Verwaltungs, an estimated $7.71M sold.
Based on aggregated 13F filings for Q4 2025.